 |
40 Diseases |  |
13 Trials |
|
13 Trials |  |
221 News |  |
| «123 |
- ||| oxycodone/naloxone ER / Generic mfg.
Enrollment open, HEOR: Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives (clinicaltrials.gov) - Jun 26, 2013
P=N/A, N=200, Recruiting, Sponsor: Mundipharma AB
Not yet recruiting --> Recruiting
- || oxycodone/naloxone ER / Generic mfg.
New P3 trial: Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain (clinicaltrials.gov) - Jun 20, 2013
P3, N=230, Recruiting, Sponsor: Mundipharma
- ||||| Palexia RP (tapentadol extended release) / Assertio, J&J, Grunenthal, Collegium Pharma
New P4 trial: Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component. (clinicaltrials.gov) - Apr 22, 2013
P4, N=367, Completed, Sponsor: Gr
- |||| oxycodone/naloxone ER / Generic mfg.
Trial completion: OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) (clinicaltrials.gov) - Mar 25, 2013
P2, N=120, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Not yet recruiting --> Recruiting Recruiting --> Completed
- oxycodone/naloxone ER / Generic mfg.
New P4 trial, Surgery: Oral Oxycodone After Major Cardiac Surgery (clinicaltrials.gov) - Mar 20, 2013
P4, N=50, Completed, Sponsor: Medical University of Vienna
- ||||| oxycodone/naloxone ER / Generic mfg.
New P4 trial: An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY) (clinicaltrials.gov) - Mar 12, 2013
P4, N=260, Active, not recruiting, Sponsor: Mundipharma Korea Ltd
- | oxycodone/naloxone ER / Generic mfg.
New P4 trial: An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders (clinicaltrials.gov) - Mar 12, 2013
P4, N=237, Recruiting, Sponsor: Mundipharma
- ||| oxycodone controlled release / Generic mfg.
Enrollment change: A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients (clinicaltrials.gov) - Mar 12, 2013
P4, N=128, Recruiting, Sponsor: Mundipharma Pte Ltd.
Recruiting --> Completed N=170 --> 128
- |||| pregabalin / Generic mfg.
Enrollment open: A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) (clinicaltrials.gov) - Feb 4, 2013
P4, N=119, Recruiting, Sponsor: Mundipharma Pte Ltd.
N=170 --> 128 Not yet recruiting --> Recruiting
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion: Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Nov 28, 2012
P3, N=600, Completed, Sponsor: Purdue Pharma LP
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- oxycodone/naloxone ER / Generic mfg.
Clinical: PROspective Non-interventional Open Label Trial for Assessment in Routine Practice of the Efficacy and the Safety of TARGIN ® in Korean Patients With Cancer Pain (PROBE) (clinicaltrials.gov) - Oct 30, 2012
P=N/A, N=512, Recruiting, Sponsor: Mundipharma
- | oxycodone/naloxone ER / Generic mfg.
New P4 trial, Adverse events: Quality of postoperative pain control and incidence and severity of nausea, vomiting, constipation, sedation, vertigo and somnolence during the treatment of postoperative pain with Palexia® compared to Targin®. Klinischer Vergleich zweier Schmerztherapie- Regimes nach unfallchirurgischen Eingriffen hinsichtlich Qualität der Schmerzerleichterung und Häufigkeit und Schwere von Nebenwirkungen. (EUDRACT) - Oct 23, 2012
P4, N=266, Ongoing, Sponsor: KKRN Katholisches Klinikum Ruhrgebiet Nord GmbH
- | oxycodone/naloxone ER / Generic mfg.
New P4 trial, HEOR: A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact (clinicaltrials.gov) - Oct 17, 2012
P4, N=1800, Recruiting, Sponsor: Mundipharma CVA
- | oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P4 trial: Opioidien aiheuttama mahasuolikanavan toiminnanhäiriö keisarileikkauspotilailla (EUDRACT) - Sep 12, 2012
P4, N=90, Ongoing, Sponsor: Merja Kokki
- ||||| pregabalin / Generic mfg.
New P4 trial: A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) (clinicaltrials.gov) - Aug 28, 2012
P4, N=119, Recruiting, Sponsor: Mundipharma Pte Ltd.
- ||||| oxycodone/naloxone ER / Generic mfg.
Enrollment change: Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms (clinicaltrials.gov) - May 16, 2012
P3, N=205, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Active, not recruiting --> Completed N=300 --> 205
- ||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion: Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms (clinicaltrials.gov) - May 16, 2012
P3, N=205, Completed, Sponsor: Mundipharma Research GmbH & Co KG
N=300 --> 205 Active, not recruiting --> Completed
- oxycodone/naloxone ER / Generic mfg.
Trial completion, Surgery: A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery (clinicaltrials.gov) - Feb 16, 2012
P4, N=165, Completed, Sponsor: Kati Järvelä
Active, not recruiting --> Completed Recruiting --> Completed
- | oxycodone/naloxone ER / Generic mfg.
New P4 trial, Surgery: ORAL ABSORPTION OF OXYCODONE AFTER CARDIAC BYPASS SURGERY OKSIKODONIN PER OS IMEYTYMINEN SYDÄMEN OHITUSLEIKKAUKSEN JÄLKEEN (EUDRACT) - Feb 7, 2012
P4, N=120, Ongoing, Sponsor: Mikko Hippeläinen
- ||| pregabalin / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment change: A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy (clinicaltrials.gov) - Jan 25, 2012
P2, N=98, Completed, Sponsor: Mundipharma Research GmbH & Co KG
Recruiting --> Completed N=80 --> 98
- | oxycodone/naloxone ER / Generic mfg.
Trial termination: OXN3505: Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients (clinicaltrials.gov) - Nov 14, 2011
P3, N=188, Terminated, Sponsor: Mundipharma SAS
N=80 --> 98 Recruiting --> Terminated; Lack of recruitment
- | oxycodone/naloxone ER / Generic mfg.
Enrollment change: OXN3505: Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients (clinicaltrials.gov) - Nov 14, 2011
P3, N=188, Terminated, Sponsor: Mundipharma SAS
Recruiting --> Terminated; Lack of recruitment N=624 --> 188
- |||| paracetamol / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion: A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis (clinicaltrials.gov) - Oct 31, 2011
P4, N=247, Completed, Sponsor: Napp Pharmaceuticals Limited
N=624 --> 188 Active, not recruiting --> Completed
- |||||||||| oxycodone/naloxone ER / Generic mfg.
New P3 trial: A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain (clinicaltrials.gov) - Sep 20, 2011
P3, N=172, Completed, Sponsor: Mundipharma Research GmbH & Co KG
- |||||||||| oxycodone/naloxone ER / Generic mfg.
New P3 trial, Head-to-Head: A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy (clinicaltrials.gov) - Sep 20, 2011
P3, N=270, Active, not recruiting, Sponsor: Mundipharma Research GmbH & Co KG
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P3 trial: A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain (clinicaltrials.gov) - Aug 30, 2011
P3, N=900, Recruiting, Sponsor: Purdue Pharma LP
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
New P3 trial: Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain (clinicaltrials.gov) - Aug 30, 2011
P3, N=600, Recruiting, Sponsor: Purdue Pharma LP